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doi:10.1016/j.jfma.2011.09.005Background/Purpose: A possible means of decreasing prostate cancer mortality is through
improved early detection. We attempted to create an equation to predict the likelihood of
having prostate cancer.
Methods: Between January 2005 and May 2008, patients who received prostate biopsies were
retrospective evaluated. The relationship between the possibility of prostate cancer and the
following variables were evaluated: age; serum prostate specific antigen (PSA) level, prostate
volume, numbers of prostatic biopsies, digital rectal examination (DRE) findings, and the pres-
ence of hypoechoic nodule under transrectal ultrasonography.
Results: A multivariate regression model was created to predict the possibility of having pros-
tate cancer, and a receiver-operating characteristic (ROC) curve was drawn based on the
predictive scoring equation. Using a predictive equation, PZ 1/(1 ex), where XZ
4.88, þ 1.11 (if DRE positive), þ 0.75 (if hypoechoic nodule of prostate present), þ 1.27
(when 7< PSA 10),þ 2.02 (when 10< PSA 24),þ 2.28 (when 24< PSA 50),þ 3.93 (when
50 < PSA), þ 1.23 (when 65 < age  75), þ 1.66 (when 75 < age), followed by ROC curve
analysis, we showed that the sensitivity was 88.5% and specificity was 79.1% in predicting
the possibility of prostate cancer.
Conclusion: Clinicians can tailor each patient’s follow-up according to the nomogram based on
this equation to increase the efficacy of evaluating for prostate cancer.
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696 J.-C. Wang et al.Prostate cancer is the most common solid malignancy in
men, with an estimated 218,890 new cases and 27,050
deaths in 2007 in the United States.1 From a literature
review, the specific cause has not yet known, but consid-
erable evidence suggests that both genetics and environ-
ment play a role in the origin and evolution of this disease. A
possible means of decreasing the prostate cancer mortality
is through improved early detection. Recent studies have
shown that the measurement of serum prostate specific
antigen (PSA) concentration in addition to digital rectal
examination (DRE) and transrectal ultrasonography (TRUS)
of the prostate enhances the early detection of prostate
cancer.2,3 However, there is controversy about how these
tests should be used because they have appreciable false-
negative and false-positive results.4 False-negative rates
remain of concern, with estimates that an office-based
TRUS-guided biopsy misses about 30% of clinically signifi-
cant prostate cancer.5 The aim of our study is to determine
the independent predictors of prostate cancer and develop
a multivariate logistic regression equation to predict its
occurrence. These predicting variables include age, PSA
level, prostate volume, DRE, and numbers of biopsies and
hypoechoic prostate nodules.Materials and methods
Patients who received TRUS-guided biopsies of the prostate
were retrospectively evaluated and enrolled in the study
from January 2005 to May 2008 in a medical center in
southern Taiwan. The ethics committee of the hospital
approved this study. Medical charts were reviewed and
laboratory data were collected from each patient. None of
the men had any of the following signs or symptoms of
prostate disease: hematuria, hematospermia, dysuria,
frequency, urgency, weak urine stream, or bone pain. They
all underwent TRUS-biopsy of the prostate with surgical
ultrasonography (Biplane transducer 8808 mode, 10 MHz, BK
Medical, Herlev, Denmark). The key indications for TRUS
prostate biopsy were abnormal DRE (including indurations,
asymmetry, or irregularities of the prostate), hypoechoic
prostate lesions on ultrasound examination, or abnormal PSA
level (>4 ng/dl; Chemiluminescent Microparticle Immuno-
assay, ARCHITECT System, Abbott IrelandDiagnostic Division,
Sligo, Ireland). Urology surgeons performed all DREs, even
among healthy individuals. Blood samples were obtained
before or at least 1 week after the DRE. The data extracted
from charts included the most recent serum PSA level, DRE
findings, number of biopsies, and pathologies of biopsies.
Pathologic information was collected from surgical reports,
and clinical information, including DRE findings, prostate
volume and numbers of biopsies were collected primarily
from a standard form completed by the treating physician
on the day of the procedure. Other clinical information,
including patient age and PSA level, were obtained from all
other documents available in the patients’ medical records.
The relationships between age, prostate volume,
number of biopsies, PSA level, DRE findings, presence of
hypoechoic prostate nodules, and pathology reports were
evaluated.
Using ultrasound for TRUS-guided prostate biopsy was an
office-based procedure, performed under local anesthesiawith patients in the left-lateral decubitus position. The
probe was inserted transrectally and the sonograms were
displayed simultaneously in the transverse and sagittal
planes. Before the procedure, all men were given enemas
containing phosphate and sodium biphosphate, as well as
antimicrobial prophylaxis.
Biopsies were performed by urologists and the numbers
of biopsies from each patient were all 10 specimens. If
there were obvious hypoechoic prostate lesions on the
ultrasound images, five specimens were taken from those
areas, while the remaining specimens were obtained
randomly from the peripheral and transitional zones of
each lobe. If no hypoechoic prostate lesion was observed on
TRUS imaging, all specimens were randomly obtained from
the peripheral and transitional zones of each lobe equally.
Data were expressed as means standard deviations
(SD) or count (percentage), as appropriate. Student’s t test
was for continuous variables and a chi-square test was
completed for categorical variables to compare the
difference between two groups. The forward stepwise
procedure was performed to construct a multiple logistic
regression model, equating the relationships between
clinical characteristics and occurrence of prostate cancer.
A nonsignificant result (pZ 0.152) of Hosmer and Leme-
show test supported the goodness-of-fit of our model.
According to the equation, clinicians may rapidly calculate
each patient’s score (logit value) and used the nomogram to
yield a predicted probability of prostate cancer. Moreover,
we used the likelihood to plot receiver operating charac-
teristic (ROC) curve and found out an optimal cut-off point
of predicted probability by maximizing the Youden Index.
Sensitivity and specificity of this cut point was assessed. All
data were analyzed using a qualified statistical software
package (SPSS for Windows, Version 16.0, SPSS Inc., Chi-
cago, Illinois, USA). A p of less than 0.05 was considered
significant.Results
Among the 356 men suspected of having prostate cancer,
the mean age was 66.9 9.9 years (range, 35e89 years).
Prostate cancer occurred in 87 men (24.4%). The mean age
of these 87 patients was 72.2 8.0 years (range, 54e86
years). A total of 323 men (90.7%) had serum PSA concen-
trations of greater than 4.0 ng/ml, 131 (36.7%) had
abnormal findings on DRE, and 130 (36.5%) had hypoechoic
prostate nodules on TRUS imaging. We found that 119
(33.4%) had PSA >4 ng/ml with abnormal DRE findings, 109
(30.6%) had PSA >4 ng/ml with hypoechoic prostate
nodules on TRUS imaging, and 71 (19.9%) had abnormal DRE
findings with hypoechoic prostate nodules on TRUS imaging.
A total of 62 (17.4%) patients met all of the three inclusion
criteria. Patients and their clinical characteristics are
summarized in Table 1.
Patients with prostate cancer were older and more likely
to have a higher PSA level than the noncancer group (Table 2,
both p< 0.001). Positive findings in DRE and hypoechoic
prostate nodules were also significantly higher in the cancer
group. (Table 2, p< 0.001, pZ 0.005, respectively).
Multivariate logistic regression was performed on the
significant variables extracted from the previous step to
Table 1 Detecting rate of prostate cancer in various combinations.
Variables Cancer p
Total count, % No. count, % Yes count, %
DRE  224 (63.1) 198 (73.9) 26 (29.9) <0.001
þ 131 (36.9) 70 (26.1) 61 (70.1)
Hypoechoic nodule  226 (63.5) 191 (71.0) 35 (40.2) <0.001
þ 130 (36.5) 78 (29.0) 52 (59.8)
PSA (ng/ml) 4 33 33 (12.3) 0 (0) <0.001
>4 323 (90.7) 236 (87.7) 87 (100)
PSA >4 and DRE (þ) No 236 (66.5) 210 (78.4) 26 (29.9) <0.001
Yes 119 (33.5) 58 (21.6) 61 (70.1)
PSA >4 and hypoechoic nodule (þ) No 247 (69.4) 212 (78.8) 35 (40.2) <0.001
Yes 109 (30.6) 57 (21.2) 52 (59.8)
DRE (þ) and hypoechoic nodule (þ) No 284 (80.0) 239 (89.2) 45 (51.7) <0.001
Yes 71 (20.0) 29 (10.8) 42 (48.3)
PSA >4 and DRE (þ) and hypoechoic nodule (þ) No 293 (82.5) 248 (92.5) 45 (51.7) <0.001
Yes 62 (17.5) 20 (7.5) 42 (58.3)
DREZ digital rectal examination; PSAZ prostate specific antigen.
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with prostate cancer. Thus, the final model contained four
variables: age, five PSA levels, DRE, and hypoechoic pros-
tate nodules. The results showed AGE2 (65< age 75; odds
ratio [OR]Z 3.43, confidence interval [CI]Z 1.44e8.19,
pZ 0.006), AGE3 (75< age; ORZ 5.27, CIZ 2.13e13.05,
p< 0.001), DRE (ORZ 3.05, CIZ 1.57e5.92, pZ 0.001),
hypoechoic prostate nodules (ORZ 2.11, CIZ 1.10e4.07,
pZ 0.026), PSA2 (7< PSA 10; ORZ 3.57, CIZ 1.07e
11.95, pZ 0.039), PSA3 (10< PSA 24; ORZ 7.51,
CIZ 2.65e21.30, p< 0.001), PSA4 (24< PSA 50; ORZ
9.76, CIZ 2.71e35.12, p< 0.001), and PSA5 (50< PSA;
ORZ 50.94, CIZ 15.43e168.12, p< 0.001) wereTable 2 Association between clinical characteristics and prosta
Variables
No (nZ 269)
Age (y)a 66.9 9.9
Biopsy no.a 12.0 2.4
Prostate volume (ml)a 48.4 38.3
DREb  198 (88)
þ 70 (53)
Hypoechoic noduleb  191 (85)
þ 78 (60)
PSA (ng/ml)a 59.7 174.8
PSA stratificationb 2.50 22 (100)
2.51e4.00 11 (100)
4.01e10.00 141 (92)
>10.01 95 (56)
Digits in cells represent mean SD or count (percentage).
a Data were compared by Student’s t test.
b Data were compared by chi-square test.independently associated with prostate cancer (Table 3).
No matter PSA level and age are continuous factors or
stratified factors; they are independent factor in evalu-
ating prostate cancer (Tables 2 and 3). We put PSA level
and age as stratified factors into the predictive model of
prostate cancer because of no evidence showed PSA level
or age has linear relationship with prostate cancer. And the
stratification of PSA level and age are according to the
method of making minimal statistic bias in numbers.
The predicted probability (P) of having prostate cancer
was estimated by the multiple logistic regression model:
PZ 1/(1ex), where XZ4.88þ 1.11 (if DRE positive)þ
0.75 (if hypoechoic nodule present)þ 1.27 (when 7< PSAte cancer.
Cancer p
Yes (nZ 87) Total (nZ 356)
67.7 9.8 72.2 8.0 <0.001
12.1 2.3 11.7 2.9 0.260
49.8 41.7 44.3 24.8 0.137
26 (12) 224 (100) <0.001
61 (47) 131 (100)
35 (16) 226 (100) <0.001
52 (40) 130 (100)
20.7 67.4 180.3 304.2 <0.001
0 (0) 22 (100) <0.001
0 (0) 11 (100)
13 (8) 154 (100)
74 (44) 169 (100)
Table 3 Multivariate logistic regression model to predict
the risk of prostate cancer.
Variables B OR (eB) 95% CI of OR p
DRE No Ref. Ref.
Yes 1.11 3.05 1.57e5.92 0.001
Hypoechoic
nodule
No Ref. Ref.
Yes 0.75 2.11 1.10e4.07 0.026
PSA
(ng/ml)
7 Ref. Ref.
>7e10 1.27 3.57 1.07e11.95 0.039
>10e24 2.02 7.51 2.65e21.30 <0.001
>24e50 2.28 9.76 2.71e35.12 <0.001
>50 3.93 50.94 15.43e168.12 <0.001
Age 65 Ref. Ref.
>65e75 1.23 3.43 1.44e8.19 0.006
>75 1.66 5.27 2.13e13.05 <0.001
Intercept 4.88 0.01 <0.001
BZ regression coefficient; ORZ odds ratio in favor of having
prostate cancer; RefZ referent group. Figure 2 Receiver-operating characteristic curve. Points
(black arrow) on the receiver-operating characteristic curve
represent the possibility levels generated from the logistic
regression analysis that was used to select the optimal cut
point. A predicted probability of 0.23 provided a sensitivity of
88.5% and a specificity of 79.1%.
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 50)þ 3.93 (when 50< PSA)þ 1.23 (when 65< age 75)þ
1.66 (when 75< age). This is also shown as Fig. 1. The
predictors of the model were selected by a stepwise proce-
dure. Using a ROC curve analysis based on the prognostic
model score, a cut point for prediction of prostate cancer (P)
was defined as a value0.23. The sensitivity of the equation
was 88.5%, while the specificity was 79.1% for predicting the
possibility of prostate cancer [area under the curveZ 0.89,
95% CIZ 0.85e0.93 (Fig. 2)]. And the ROC curve of these four
combined factors is better than the ROC curve of each of
these four factors (data not showed here).
Discussion
DRE has always been the primary method for evaluating the
prostate. However, Smith and Catalona6 showed that the DRE
was investigator-dependent and had great interexaminerFigure 1 An equation predicting likelihood of prostate
cancer.variability. Jacobsen and others7 reported that one of the
effects of DRE screening for prostate cancer was that men
screened with DRE were less likely to die from prostate
cancer, and screening could have prevented 50%e70% of
prostate cancer deaths. However, both Friedman et al8 and
Chodak et al9 showed little or no additional beneficial effect
for DRE in a screening program. In our study, the univariate
analysis showed that DRE had a relationship with prostate
cancer (p< 0.001). With multiple logistic regression
modeling, the adjustedOR for predicting prostate cancerwas
significant for DRE (ORZ 3.05, CIZ 1.57e5.92, pZ 0.001).
Our results revealed DRE is an independent predictor of
prostate cancer, which is consistent with former reports.
TRUS is widely available for most physicians and has
become the most commonly used imaging modality for the
prostate.10 It detects cancers as hypoechoic lesions, but
finding a hypoechoic lesion is not specific for prostate
cancer because benign processes, such as prostatitis or
infarction,10 also appear as hypoechoic lesions. In Dyke’s11
study, the group consisted of 164 consecutive men with
a solitary hypoechoic prostatic nodule visible at TRUS, and
carcinoma was diagnosed on the basis of biopsy directed at
the suspicious hypoechoic nodule alone in 56 patients
(79%).11 In our study, the results of a univariate analysis
showed that the hypoechoic prostate nodule had a rela-
tionship with prostate cancer (p< 0.001). In the multiple
logistic regression analysis, the adjusted OR for predicting
prostate cancer was significant for hypoechoic nodules
(ORZ 3.05, CIZ 1.10e4.07, pZ 0.026). Our results
showed that the presence of a hypoechoic prostate nodule
is an independent predictor for prostate cancer.
PSA is a protein that is produced by the prostatic
epithelium. It is sufficiently specific for the prostate gland
in clinical practice. Although PSA is organ-specific, it is not
Figure 3 (A) An example of a patient’s clinical data; (B) a rapid scoring system using a logistic regression model; (C) a nomogram
for calculating the predicted probability of prostate cancer.
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cause serum PSA to rise.12 Furthermore, PSA values can be
influenced by prostate manipulation, e.g., DRE, TRUS, or
cystoscopy, and, to a variable degree, acute prostatitis and
urinary retention can also affect the PSA value.13 Rarely
happened prostate infarction can also affect PSA level
greatly.14 In the study by Chris et al,13 who evaluated the
screening tests for detection of prostate cancer of 1726
men, total serum PSA was the most important single
predictor of prostate cancer, followed by DRE. In our study,
to minimize statistical bias, we separated patients into five
different categories of PSA levels (Table 3); they were all
related to prostate cancer, but they had different contri-
butions to prostate-cancer likelihood. The higher the PSA
level, the greater the contribution was.
The factors that determine the risk of developing pros-
tate cancer are not well known; however, some have been
identified. Age is the most obvious risk factor with the
incidence of the disease increasing with age. About 75% of
patients with prostate cancer are diagnosed after 65 years
of age.14 A 75-year-old man has an average life expectancy
of another 10 years, so very few men aged 75 years or older
would experience a mortality benefit. Regardless of
whether or not age was treated as a continuous or cate-
gorical variable, it always had a statistically significant
relationship with the prostate cancer. Thus, we divided age
into three groups: Group 1 (age 65 years), Group 2
(65< age 75 years), and Group 3 (age >75 years). Group 1
served as the baseline for comparison. The contribution of
age as a risk factor for prostate cancer as shown in Table 3.
We combined ROC curve analysis and the multivariate
logistic regression equation to evaluate the predictive
accuracy of the four variables for predicting the possibilityof prostate cancer. All four of the variables, which have
been previously shown to be related to prostate cancer,
had good accuracy for predicting the possibility of prostate
cancer, with sensitivity of 88.5% and specificity of 79.1%.
Since these four variables in the scoring model were clini-
cally simple to attain, we considered that the derived
equation was clinically useful to predict the possibility of
prostate cancer in daily practice.
At our hospital, clinicians do not need to remember the
equation because we programmed it into Microsoft Excel
(Microsoft Corporation, USA) on the outpatient department
computer. When clinicians suspect prostate cancer, they
input the patient’s PSA level, age, DRE findings (1 if positive
finding and 0 for negative) and the presence or absence of
a hypoechoic prostate nodule (1 for present and 0 for not)
into the established input data column (Fig. 3A). The
computer will then calculate the final total score (Fig. 3B).
Finally, they examine Fig. 3C to get the estimated likeli-
hood of prostate cancer for the patient. Clinicians can tell
patients the possibility of having prostate cancer according
to these four easily obtained variables and can tailor each
patient’s follow-up treatment accordingly. Therefore,
patients may become more willing to undergo TRUS-guided
biopsy to increase the efficacy of screening for prostate
cancer.
Our analysis has limitations. It is a retrospective study
and the prostate cancer risk equation developed has not
yet been validated. Despite these limitations, our equation
is based on the variables obtained from patients within the
same race and in a local environment; thus, we believe it
will be useful in the design of further studies because
genetics and the environment play roles in the initial
disease and its evolution.
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